Leading global medical technology company Becton, Dickinson and Company (BDX - Free Report) introduced a new diagnostic instrument BD Phoenix M50 ID/AST. The new instrument helps in rapid identification of bacteria and detection of antimicrobial resistance. The system requires no preventative maintenance. In addition to this, the system offers multiple languages, facilitating broader adoption in laboratories around the world.
The BD Phoenix M50 system also offers integration with multiple other analyzers, including the BD BACTEC and BD Bruker MALDI Biotyper systems. This is done through BD EpiCenter middleware connectivity that enables data traceability and security.
Based in Franklin Lakes, NJ, Becton, Dickinson, popularly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents.
An innovative product pipeline is the key growth driver at BD. A huge number of regulatory approvals both in the U.S. and international markets are facilitating expansion of the company’s product portfolio. The company also has a partnership with Central Admixture Pharmacy Services (CAPS) under which BD Intelliport Medication Management System customers will be allowed to buy a portfolio of the frequently used CAPS pre-filled anesthesia syringes. We believe that such partnerships and collaborations will lend BD a competitive edge and eventually boost its overall results. Although the Zacks Consensus Estimate for the full year has remained unchanged at $8.56 over the last seven days, it reflects year-over-year growth of almost 19.6%.
Zacks Rank & Key Picks
Currently, BD carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical sector are CryoLife Inc. (CRY - Free Report) , IDEXX Laboratories Inc. (IDXX - Free Report) and Masimo Corporation (MASI - Free Report) . All these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
CryoLife has recorded a year-to-date return of 63.0%, better than the S&P 500’s 6.1% over the same time frame. In fact, the company posted positive earnings surprises in the last four quarters, the average being 502.50%.
IDEXX has a strong year-to-date return of 54.6%. The company also surpassed estimates in the last four quarters at an average rate of 12.7%.
Masimo has an impressive long-term expected earnings growth rate of 15% and a solid year-to-date return of 43.3%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>